Монголын анагаах ухаан, 2015, 2(172)
PGC-1α генийн полиморфизмыг БСХШ-ийн зарим эрсдэлт хүчин зүйлтэй холбон судалсан дүн
( Судалгааны өгүүлэл )
АШУҮИС, ЭЗ-БиоАС, Эсийн биологи, Биохимийн тэнхим
Өгүүллийн PDF-ийг татах
Абстракт
Introduction: The metabolic syndrome (MS) is characterized by central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL), increase blood pressure and raise fasting plasma glucose. The PGC-1α gene is located on chromosome 4 p.15.1 in humans and encodes a protein containing 798 amino acids. The protein encoded by this gene is a transcriptional coactivator that regulates the genes involved in energy metabolism. PPARγ, a coactivator molecule recently identified based on its ability to interact with PPARγ, is involved in many important metabolic processes, including adaptive thermogenesis, mitochondrial biogenesis and fatty acid β–oxidation.
Goal: To study the frequency of PGC-1α Gly482Ser polymorphism in people with MS in relation to the risk factors of the MS.
Materials and methods: The study population comprised 302 unrelated Mongolian subjects (158 with metabolic syndrome and 144 controls). The genotypes for polymorphism of candidate gene related to MS were determined using a RFLP analysis of the MspI digest of the PCR product.
Result: From the control group, 33.4% (48) had GG, 47.2% (68) had GS and 19.4% (28) had SS genotypes. 51.9% (82) of people with MS had GG, 35.4% (56) had GS and 12.7% (20) had SS genotypes. The prevalence of G allele in people with MS was 69.6%, which is much higher than healthy group. Comparing PGC-1α Gly482Ser GG, GS and SS genotypes with systolic arterial blood pressure revealed statistically significant difference which was higher among subjects with GG genotype. The blood pressure of people with MS and carrying GG genotype of PGC-1α Gly482Ser polymorphism was significantly increased 2.35 times than people without MS.
Conclusions:
- 69.6 percentages of the people with MS had G allele and 2.2 times more than those without metabolic syndrome.
- We determined that the odds ratio for the high blood pressure and it was 2.35 times higher in people with GG allele of Gly482Ser carriers than GS and SS alleles carriers (OR = 2.35, p = 0.012).
Key words: metabolic syndrome, PGC-1α gene, Gly482Ser polymorphisms, arterial hypertension
Pp. 18-21, Tables 2, References 9
Ном зүй
1. Liu, C. and J.D. Lin, PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin (Shanghai), 2011. 43(4): p. 248- 57.
2. Knutti, D. and A. Kralli, PGC-1, a versatile coactivator. Trends Endocrinol Metab, 2001. 12(8): p. 360-5.
3. Ek, J., et al., Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia, 2001. 44(12): p. 2220-6.
4. Esterbauer, H., et al., Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics, 1999. 62(1): p. 98- 102.
5. Guo, L. and R. Tabrizchi, Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther, 2006. 111(1): p. 145-73.
6. Gupta, A.C., et al., Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol Int, 2010. 5(1): p. 575-80.
7. Sookoian, S., et al., Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol, 2005. 35(2): p. 373-80.
8. Oberkofler, H., et al., Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension, 2003. 41(2): p. 368-72.
9. Fanelli, M., et al., The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers, 2005. 21(4): p. 175-80.
2. Knutti, D. and A. Kralli, PGC-1, a versatile coactivator. Trends Endocrinol Metab, 2001. 12(8): p. 360-5.
3. Ek, J., et al., Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia, 2001. 44(12): p. 2220-6.
4. Esterbauer, H., et al., Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics, 1999. 62(1): p. 98- 102.
5. Guo, L. and R. Tabrizchi, Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther, 2006. 111(1): p. 145-73.
6. Gupta, A.C., et al., Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol Int, 2010. 5(1): p. 575-80.
7. Sookoian, S., et al., Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol, 2005. 35(2): p. 373-80.
8. Oberkofler, H., et al., Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension, 2003. 41(2): p. 368-72.
9. Fanelli, M., et al., The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers, 2005. 21(4): p. 175-80.
Танилцаж нийтлэх санал өгсөн : Анагаах ухааны доктор, профессор И.Пүрэвдорж
Нийтлэлийн нээгдсэн тоо: 423
